Robert E. Landry - Mar 31, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Mar 31, 2022
Transactions value $
-$450,357
Form type
4
Date filed
4/1/2022, 04:07 PM
Previous filing
Mar 30, 2022
Next filing
Apr 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $599K +1.5K +5.22% $399.66 30.2K Mar 31, 2022 Direct F1
transaction REGN Common Stock Tax liability -$830K -1.18K -3.91% $700.99 29.1K Mar 31, 2022 Direct F1
transaction REGN Common Stock Sale -$209K -301 -1.04% $695.50 28.8K Apr 1, 2022 Direct F1
transaction REGN Common Stock Sale -$10.5K -15 -0.05% $701.98 28.7K Apr 1, 2022 Direct F1
holding REGN Common Stock 229 Mar 31, 2022 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.5K -30% $0.00 3.5K Mar 31, 2022 Common Stock 1.5K $399.66 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.